0
0 (0%)
Cell Source, Inc. [CLCS]
Source:
Company Overview
Cell Source, Inc. is a cell therapy company focused on immunotherapy. Since our inception, we have been involved with the development of proprietary immune system management technology (“Cell Source technology”) licensed from Yeda Research & Development Company Limited (“Yeda”),the commercial arm of the Weizmann Institute of Science (“Weizmann Institute”) in Israel.
| Country | United States |
| Headquarters | new york, new york |
| Phone Number | (646) 416-7896 |
| Industry | manufacturing |
| CEO | Itamar Shimrat |
| Website | cell-source.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-0.8 |
| Net Income | $-1.4 |
| Net Cash | $0 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -616.4% |
| Profit as % of Stockholder Equity | 7.5% |
Management Effectiveness
| Return on Equity | 7.5% |
| Return on Assets | -535.5% |
| Turnover Ratio | |
| EBITA | $-0.8 |
Balance Sheet and Cash Flow Measures
| Total Assets | $0.3 |
| Total Liabilities | $19.2 |
| Operating Cash Flow | $-1.9 |
| Investing Cash Flow | |
| Financing Cash Flow | $1.9 |
